Amgen Gets US Infliximab Nod
Amgen’s Avsola Rival To Remicade Is Its Fourth FDA-Approved Biosimilar
Amgen has received its fourth US biosimilar approval for its Avsola infliximab rival to Janssen’s Remicade.
You may also be interested in...
Amgen’s biosimilar revenues were more than $350m in the second quarter of this year, as the company benefitted from the ‘innovator product’ commercialization model across its increasingly broad portfolio of biosimilars.
Without the newly purchased drug, Amgen’s 2020 sales would be flat, but the company hopes to enhance its psoriasis market push with its combined offering of Otezla, Enbrel and biosimilars.
Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News
The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.